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After breast conserving surgery, early stage breast cancer patients are currently treated
with a wide range of radiation techniques including whole breast irradiation (WBI), accel-
erated partial breast irradiation (APBI) using high-dose rate (HDR) brachytherapy, or 3D-
conformal radiotherapy (3D-CRT). This study compares the mean heart’s doses for a left
breast irradiated with different breast techniques. An anthropomorphic Rando phantom was
modified with gelatin-based breast of different sizes and tumors located medially or later-
ally. The breasts were treated with WBI, 3D-CRT, or HDR APBI. The heart’s mean doses
were measured with Gafchromic films and controlled with optically stimulated lumines-
cent dosimeters. Following the model reported by Darby (1), major cardiac were estimated
assuming a linear risk increase with the mean dose to the heart of 7.4% per gray. WBI
lead to the highest mean heart dose (2.99 Gy) compared to 3D-CRT APBI (0.51 Gy), multi-
catheter (1.58 Gy), and balloon HDR (2.17 Gy) for a medially located tumor. This translated
into long-term coronary event increases of 22, 3.8, 11.7, and 16% respectively. The sensi-
tivity analysis showed that the tumor location had almost no effect on the mean heart dose
for 3D-CRT APBI and a minimal impact for HDR APBI. In case of WBI large breast size and
set-up errors lead to sharp increases of the mean heart dose. Its value reached 10.79 Gy for
women with large breast and a set-up error of 1.5 cm. Such a high value could increase the
risk of having long-term coronary events by 80%. Comparison among different irradiation
techniques demonstrates that 3D-CRT APBI appears to be the safest one with less proba-
bility of having cardiovascular events in the future. A sensitivity analysis showed that WBI
is the most challenging technique for patients with large breasts or when significant set-up
errors are anticipated. In those cases, additional heart shielding techniques are required.
Keywords: breast neoplasms, radiotherapy, heart diseases, brachytherapy, radiation dosage
INTRODUCTION
In developed countries, breast cancer is the most common type of
cancer in women (2, 3). With implementation of mammographic
screening, the majority of the cases are diagnosed at an early
stage. The standard treatment for early stage breast cancer includes
removing the tumor and sampling the axillary lymph nodes using
limited surgery (4). This is followed by whole breast radiotherapy
and possibly regional radiation if nodes are positive. Currently,
there is a general trend toward treatment de-escalation. Radiation
oncology studies demonstrate that the duration of whole breast
irradiation (WBI) can be shortened from 6 to 3 weeks (5–7), and
other showing that for selected cases the amount of irradiated
breast tissue could be limited to a small portion surrounding the
surgical cavity (8, 9). This leads to a technique called accelerated
partial breast irradiation (APBI). It combines a reduction of the
irradiated breast volume and delivery of higher dose per fraction.
Multiple APBI techniques have been proposed including exter-
nal beam 3D-conformal radiotherapy (3D-CRT), high-dose rate
(HDR) interstitial brachytherapy using multicatheter or balloon,
and permanent breast seeds implants (10, 11). As a result, patients
with early stage breast cancers are treated with a variety of radia-
tion techniques that appears comparable in terms of effectiveness
(12, 13).
Along with the changes in radiation oncology practice men-
tioned above, the increased early detection of breast cancer due
to screening programs has also resulted into improvement of the
breast cancer treatment outcomes, with specific survival rates of
98.6% at 5 years (14). With improved survival, the reduction of
treatment induced morbidity and mortality has gained impor-
tance as they may eliminate the need for adjuvant radiotherapy.
Several studies with long-term follow-up have shown that standard
external beam radiotherapy can increase the risk of ischemic heart
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disease and a recent large case control study suggests that a dose–
response relationship between the mean dose to the heart and the
long-term risk of major cardiovascular events including mortality
(1, 15–18). It is unknown if all the radiation techniques used in
early stage breast cancer have similar cardiac risks since there are no
long-term prospective data comparing them on this specific out-
come. There is a limited number of studies reporting or comparing
the heart dose (19–25) for one or two techniques but there has not
been thorough comparison of the mean dose to the heart for all
breast techniques, for various breast sizes and/or seroma locations.
In most of cases, commercial treatment planning systems (TPS)
are used for estimation of the heart’s dose. Since this dose is calcu-
lated outside the field where photon scattering dominates, some
concern about the accuracy of those calculations exists (26, 27).
Given the inaccuracies in calculating out of field dose with the
current clinical TPS, the purpose of this study was to measure
and compare the mean heart dose for different breast irradia-
tion techniques delivered to the left breast of an anthropomorphic
phantom. In addition, the robustness of our findings was tested
using a sensitivity analysis looking at the added influence of breast
size, seroma location, and organ motion.
MATERIALS AND METHODS
PREPARATION OF PHANTOMS
An anthropomorphic Rando phantom (The Phantom Labora-
tory, Salem, NY, USA) was modified using molded pieces of a
tissue equivalent gel for mimicking various breast sizes. In order
to prepare the necessary phantom, three CT scans of patients with
left sided breast cancer having typically small (300 cc), medium
(800 cc), and large breast (1200 cc) volumes were selected from
our institution’s dosimetry database. Each CT slice was spaced by
1 cm and was printed on a scale 1:1 and used to create a realis-
tic 3D breast shape assembling several styrofoam sheets of 1 cm
thickness. The printout of the patient contour was pasted on indi-
vidual styrofoam sheets and cut following the chest wall and breast
contours (Figure 1). A negative breast mold was then made using
a thermoplastic sheet. This negative mold was then filled with a
tissue equivalent powdered ballistics gelatin (Vyse, Schiller Park,
IL, USA) dissolved in water. The breast phantom was refrigerated
overnight. The resulting gelatin phantom has an average CT num-
ber of 24 Hounsfield units (HU), which is similar to fibroglandular
breast tissue. The phantom was kept at 5°C to limit melting and
water evaporation. It was tightly fixed on the Rando phantom chest
wall for planning and treatment.
TREATMENT SIMULATION AND VOLUME DEFINITION
Treatment simulation for small, medium, and large breasts was
done following standard institution protocol (28). The Rando
phantom with various breast volumes placed on the torso was
positioned on a breast board. Five radio-opaque beads and/or pen
marks were placed on the skin in the lateral, medial, inferior, and
superior aspects of the chest to ensure treatment reproducibility.
CT slices of 5 mm spacing and 5 mm thickness were acquired with
a Philips CT scanner (Philips Healthcare, Andover, MA, USA) and
transferred to either the Pinnacle 3 (RaySearch Americas Inc., Gar-
den City, NY) or the Oncentra Brachytherapy planning systems
(Nucletron Elekta, Stockholm, Sweden).
For WBI the clinical target volume (CTV) was defined as whole
breast gel phantom limited by the Rando chest wall and a 5 mm
layer below the phantom surface. For APBI, the CTV were defined
either on the medial or the lateral quadrants of the breast. To
ensure comparison of similar target volumes, CTVs of 60 cc were
delineated. For brachytherapy, the planning target volume (PTV)
included a 1.5 cm expansion from the CTV but limited to the
Rando chest wall and 5 mm below the breast surface, while for
3D-CRT APBI the PTV included an expansion of 2.5 cm, similarly
to the NSABP-B39 protocol (29).
TREATMENT PROTOCOLS
External beam radiotherapy
Whole breast irradiation was planned following standard breast
IMRT protocol (30) using a prescription dose of 50 Gy in
FIGURE 1 | (A) Materials used during the breast phantom manufacture. (1)
Styrofoam slices cut to fit CT contours. (2) Thermoplastic 3D breast contour
obtained from the Styrofoam mold. (3–5) Small, medium, and large size of
gelatin-based breast phantoms. (B) Styrofoam slices cut to the patient profile
using CT images. (C) Thermoplastic mold over the Rando phantom modified
with the large breast to ensure good contact.
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FIGURE 2 | Fields arrangement and various breast treatments dosimetry. (A.1) Medium size WBI treatment dosimetry and (A.2) tangential fields 3D
representation. (B.1) 3D-CRT APBI dosimetry and (B.2) five fields no coplanar 3D representation. (C) Multicatheter HDR APBI dosimetry.
25 fractions. For the small and the medium-sized breast phan-
toms, the beam energy was 6 MV, while a mix of 6 and 18 MV
beams was used for the large breast volume. In this protocol, a
multileaf collimator (MLC) is used to shape several field-in-field
beams to compensate for missing tissue and to improve the dose
distribution homogeneity. Plans were normalized to a prescription
point set at mid-separation, 2/3 of the distance between skin and
a base of the tangential fields. Heart shielding involved ensuring
the anterior heart volume was away from the posterior beam edge.
Standard treatment set-up procedures were followed including
verification of each field using portal imaging.
For 3D-CRT APBI, three to five non-coplanar beams were
aimed (Figure 2) at the PTV (29, 31) and a dose of 38.5 Gy in
10 BID fractions was prescribed. The distribution was normalized
on the PTV centroid.
Treatments were delivered using a 6/18 MV Elekta Synergy linac
equipped with a multileave collimator (Elekta Inc., Crawley, UK).
Treatment was delivered after verification of the correctness of the
set-up using portal imaging.
Brachytherapy
Using a free-hand technique, 13 catheters were inserted (Figure 3)
in a triangular pattern and evenly spaced by 1.5 cm in the horizon-
tal plane and 1 cm in the vertical plane (32). The implanted Rando
phantom was CT simulated and the images were transferred to the
planning system for target segmentation and dose optimization.
A dose of 34 Gy in 10 fractions was prescribed on the minimal
peripheral dose (MPD) and dwell times were optimized using the
IPSA optimization module (33) to ensure that at least 90% of the
target volume (D90) will receive at least 90% of the prescribed dose,
and that the volume receiving more that 200% of the prescribed
dose (V200) would be <20 cc. HDR brachytherapy was delivered
using a 192Ir HDR remote afterloader (Flexitron, Elekta, Stock-
holm, Sweden). To replicate a balloon catheter HDR treatment, a
3 cm diameter surgical cavity was made in the breast gel phantom
and a Foley catheter was positioned inside before being filled with
saline. A single catheter was inserted into the Foley catheter and
used to deliver a dose of 34 Gy in 10 fractions at the point located
1 cm from the balloon surface.
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FIGURE 3 | Breast treatments. (A) Multicatheter HDR APBI. (B) Foley catheter used for balloon HDR APBI. (C) 3D-CRT APBI.
PLACEMENT OF DOSIMETERS
Two types of dosimeters were used for dose measurements, opti-
cally stimulated luminescent dosimeter (OSLD) high-accuracy
Nanodot dosimeters (Landauer Inc., Glenwood, IL, USA) and
Gafchromic EBT3 films (Ashland Inc., Covington, KY, USA).
OSLD dosimeters were placed in areas corresponding to a left
descending artery, and the center of left and right ventricles. The
detectors were placed inside a bolus material between the three
consecutive Rando phantom slices where the heart was identified
(Figure 4).
Three Gafchromic films were used to evaluate the heart’s dose
distribution in 3D. They were positioned at different location
evenly spaced by 1.5 cm. In total, 24 films were irradiated at the
three films positions (Apex, medium heart, and base of the heart).
For the each technique, films were placed between slices inside the
anthropomorphic phantom and fixed in clearly established posi-
tions for every experiment. To indicate the exact position of the
contour of the heart, the heart contour was drawn on the film with
a permanent marker.
In accordance with recommendations of AAPM TG55, the
Gafchromic films were kept in a dry and dark area at room temper-
ature for at least 24 h before reading. The heart contours identified
on the films were segmented and the optical density was found
using the Epson Expression 10000XL scanner (EPSON Deutsch-
land GmbH, Meerbusch, Germany). Optical densities were con-
verted into dose using a calibration curve. All measured dose were
expressed as a percentage of the prescribed dose. The doses mea-
sured with the 2D film were assumed to represent the average dose
absorbed in the adjacent heart’s volume and cumulative DVH were
built.
FIGURE 4 | Optically stimulated luminescent dosimeters and
Gafchromic film placement between Rando slices with a 5 mm bolus.
SENSITIVITY ANALYSIS
Except the used radiation techniques, other changing factors such
as the breast size, shape, and location of the seroma, and distance
between a heart and a field’s border or a HDR source could also
impact on the mean heart dose (34). A meaningful evaluation
of the mean heart dose should also account for potential patient
set-up error, also called inter-fraction error, for anatomical factors
such as heart volume variations between the systolic and diastolic
phases or due to patient’s phenotype. To evaluate the impact of
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those variations for various radiation techniques, the Gafchromic
films were reanalyzed shifting the heart position by 1.5 cm. This
value is the average of the distance between the field border and
the tip of the heart measured on portal imaging for the worse case
scenario group in Goody’s study (35). In this report, 11% of the
128 patients had the heart protruding in the irradiation field from
10 to 20 mm.
ESTIMATION OF MAJOR CARDIAC EVENTS
Following the model reported by Darby (1), major cardiac were
estimated assuming a linear risk increase with the mean dose to
the heart of 7.4% per gray (95% confidence interval, 2.9–14.5;
p< 0.001). Those major cardiac events include myocardial infarc-
tion, coronary revascularization, and death from ischemic heart
disease, but angina episodes are not included.
RESULTS
QUALITY ASSURANCE
The OSLD dose measurements performed inside breast of various
sizes were in very good agreement with those calculated with Pin-
nacle TPS. The dose measured using three to five detectors placed
inside the breast was 95% (SD= 2.5%) of the calculated one for
the small breast, and 101% (SD= 0.8%) of the calculated one for
the medium size breast.
A very good agreement between OSLD measurements and
the Gafchromic film measurements were received (Figure 5). A
correlation coefficient R2 of 0.98 (p< 0.001) is calculated.
MEAN DOSE TO THE HEART
The measured mean heart’s doses received with different irradia-
tion technique for medium size breast are shown in Table 1. WBI
FIGURE 5 | Correlation between OSLDs and Gafchromic films
measurements.
yielded the highest mean heart dose, 2.9 Gy, leading to an estimated
increased risk of major coronary events of 22%, while the low-
est mean heart dose was measured for the 3D-CRT APBI, 0.5 Gy,
leading to a negligible 4% increased risk of cardiac events. The
summarized cumulative DVHs for different radiation techniques
and different anatomical structures are shown on Figures 6–9.
SENSITIVITY ANALYSIS
We performed a sensitivity analysis. There was no significant dif-
ference in the value of the mean heart’s dose when the small and
medium breast size phantoms were used. At the same time, its
value doubled from 2.99 Gy to 6.39 Gy when the largest breast size
phantom was used (Table 2). This was due to the posterior shift of
the beam edge needed to fully cover the breast volume. The seroma
location had little impact when using whole breast radiotherapy
or 3D-CRT APBI. It increased the mean heart’s dose by 17%
for a medially compared to laterally located seroma using multi-
catheter brachytherapy, and by 32% using balloon brachytherapy.
This was essentially due to the closer proximity to the radioactive
source. The most dramatic increase of mean heart’s dose was seen
when we were testing set-up or organ motion errors for exter-
nal beam radiotherapy. An anterior shift of the heart’s edge by
1.5 cm resulted in a 150% increase. For a large breast volume, the
mean heart dose could reach 10.8 Gy, which corresponds to almost
a twofolds increased risk of major coronary events. The set-up
errors and organ motion effects were much less pronounced for
brachytherapy techniques and this was the consequence of the
smoother isodose gradient on the Gafchromic films anteriorly to
the heart compared to external beam with heart shielding.
Table 1 | Mean heart dose measured with Gafchromic films for the
medium (800 cc) and large breast (1200 cc) phantom using different
radiation techniques.
Technique Mean
dose (Gy)
Relative to
prescribed
dose (%)
Increased risk
of coronary events
in % (95% CI)b
WBI
Medium (800 cc) 2.99 5.99 22.0 (8.7–43.4)
Large (1200 cc)a 6.39 12.79 47.2 (18.5–92.6)
3D-CRT-APBI
Lateral 0.57 1.48 4.2 (1.7–8.3)
Medial 0.51 1.34 3.8 (1.5–7.4)
HDR MULTICATHETER
Lateral 1.44 4.28 10.6 (4.2–20.9)
Medial 1.58 4.67 11.7 (4.6–22.9)
HDR BALLOON
Lateral 1.27 3.73 9.4 (3.7–18.4)
Medial 2.17 6.38 16.0 (6.3–31.5)
aLarge pendular breast treated wide tangents.
bIncreased risk in major coronary events (myocardial infarction, coronary revas-
cularization, and death from ischemic heart disease) is 7.4% (95% confidence
interval 2.9–14.5%) per Gray (16).
WBI, whole breast irradiation; 3D-CRT APBI, 3D-conformal radiation therapy
accelerated partial breast irradiation.
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FIGURE 6 | DVHs for WBI of medium and large breasts. More heart is
receiving a higher dose for large breasts. WBI, whole breast irradiation.
FIGURE 7 | Cumulative DVHs for various adjuvant breast irradiation
techniques for a medially located tumor and a medium breast. The
3D-CRT APBI appears to be the safest by far. WBI, whole breast irradiation;
3D-CRT APBI, beam 3D-conformal radio therapy accelerated partial breast
irradiation; HDR, high-dose rate.
DISCUSSION
This work reports the mean cardiac doses measured in an
anthropometric phantom mimicking, a patient receiving breast
radiotherapy with various techniques currently used for early
FIGURE 8 | Cumulative DVHs for various tumor locations and APBI
techniques. There is no impact of location for 3D-CRT as opposed to HDR
techniques. 3D-CRT APBI, beam 3D-conformal radio therapy accelerated
partial breast irradiation; HDR, high-dose rate.
FIGURE 9 | Cumulative DVHs for the sensitivity analysis on set-up
error and motion effect for a medium sze breast and a medially located
seroma. There is little impact of those factors for HDR, but a dramatic
effect for WBI. WBI, whole breast irradiation; HDR, high-dose rate.
stage breast cancer treatment. This study provides experimental
data that could be considered more reliable compared to those
calculated in commercial TPS. According to other publications,
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Table 2 | Set-up error and organ motion sensitivity analysis of the
mean heart dose for the medium (800 cc) and large breast phantom
(1200 cc) using a 1.5 cm anterior heart shift.
Technique Mean
dose (Gy)
Relative to
prescribed
dose (%)
Increased risk of
coronary events
in % (95% CI)
WBI
Medium (800 cc) 7.11 14.22 52.6 (20.6–100)
Large (1200 cc)a 10.79 21.59 79.8 (31.3–100)
3D-CRT-APBI
Lateral 0.69 1.81 5.1 (2.0–10.0)
Medial 1.20 3.14 8.9 (3.5–17.4)
HDR MULTICATHETER
Lateral 1.68 4.97 12.4 (4.9–24.4)
Medial 1.70 5.00 12.6 (4.9–24.7)
HDR BALLOON
Lateral 1.34 3.96 9.9 (3.9–19.4)
Medial 2.44 7.19 18.1 (7.1–35.4)
aLarge pendulous breast treated wide tangents.
WBI, Whole breast irradiation; 3D-CRT APBI, 3D-conformal radiation therapy
accelerated partial breast irradiation.
commercial TPS significantly underestimate the scatter dose out-
side the irradiation field (27, 35). Howell previously reported that
the Eclipse’s analytic anisotropic algorithm gave a dose at the
point 11.25 cm away from the treatment field border less by 55%
than that of measured directly with thermoluminescent dosime-
ters (TLD) (35). To address this issue, our group used Monte
Carlo simulation to estimate the dose delivered to the left ante-
rior descending artery in an anthropometric phantom. Because
secondary photons rarely crossed the volume of interest (VOI)
the transport of a very large number of photons and multiple
variance reduction strategies were necessary. Major simplifications
have been made to the description of the phantom including large
tally volumes (36).
Yet, since very low values are expected, the measurement of scat-
tered dose remains challenging. The following quality assurance
measures were undertaken to control the validity of our measure-
ment. First, the doses at several points were checked using two
independent methods, namely, the OSLDs and the Gafchromic
films. Both are energy independent and the second one enables
capturing a 3D spatial dose distribution stacking films. Second,
we compared doses measured inside the high-dose treated volume
and those calculated by the TPS. Those checks were considered
satisfactory if they show differences in dose lower than 5%. Third,
we repeated the experiments two times to ensure no major set-up
error was made.
The most noteworthy finding of our study is that the mean heart
dose was almost halved when using HDR APBI compared to WBI,
even for the worst case scenario of a medially located left breast
tumor. In this instance, the balloon brachytherapy technique does
slightly worse, but still better than whole breast radiotherapy. The
use of 3D-CRT APBI reduced the mean heart dose to one-third
of what is received with use of HDR and to a sixth compared
to WBI. This was essentially due to the limited extension of the
posterior field border compared to WBI. It turns out the 3D-
CRT APBI is the safest radiation technique and its use has the
lowest risk of having major cardiovascular events. Those findings
are consistent with previously reported ones. In a dose model-
ing study, Hiatt reported a sixfolds dose reduction when 3D-CRT
was used instead of whole breast using IMRT (37). Also, Valach
(25) reported a mean heart’s dose of 2.45± 0.94 Gy when balloon
brachytherapy was used and the seroma was located in the inner
quadrant of the left breast. Our measured value for a similar case
was equal to 2.17 Gy.
One limitation of the present study is linked to the use of the
Rando phantom that imposes estimating the 3D mean heart’s dose
using only three Gafchromic films. Since the dose gradients are
very smooth for the APBI technique, any impact would mainly
concern the WBI technique where steep gradients are seen in the
portion of the heart close to the beam edge. However, the films
were placed perpendicular to the beam direction, such that a fine
dose resolution was obtained in 2D. It is hence unlikely that any
cold or hot spot may have been missed and that additional res-
olution would significantly change our findings. In addition, the
main goal of the present study is not to provide exact value of mean
heart’s dose since they could vary depending on many factors. The
purpose of this study was mainly to compare different breast tech-
niques, so using the same methodology enable a fair comparison
among them. Another limitation of our work relates to the conver-
sion of mean heart’s dose to major cardiovascular event risks for
each radiation technique (18). The isodose fall-off in the heart is
very different between WBI, HDR, and 3D-CRT APBI. It is much
steeper for the first one and gradual for the other ones. This leads
to very different DVH profiles and it is eventually unclear if com-
paring the mean instead of, for example, the median heart’s dose
is the right approach. Identifying the critical structures involved in
the radiation damage to the heart remains challenging. Coronary
arteries including the left anterior descending artery or ventricles
have been suggested (38). There is, however, no data correlating
the doses received on those volumes to a prospectively evaluated
clinical endpoint. We used the model proposed by Darby, as it
remains the only one showing a statistically significant correlation
between a risk of major cardiac events and a dosimetry parameter.
But, we acknowledge that the risk we calculated for the various
breast techniques maybe over or underestimated.
Using the predictive model proposed by Darby (18),a large vari-
ation in the values of the major coronary event risk is obtained. It
ranges from a negligible 4–5% increase, in case of 3D-CRT and a
medially or laterally located tumor, to a concerning 80% increase in
case of a patient with a large breast having a systematic set-up error
and/or motion exceeding 1.5 cm. This emphasizes the need of indi-
vidual evaluation of risks accounting for potential intra-fraction
errors and for patients with a large size breast with risk of set-up
error measures to reduce the dose delivered to the heart must be
taken. Those measures include gating the radiation delivery to the
breathing cycle, using a prone position, 3D-CRT APBI technique,
or proton therapy (39–41). Techniques like moderate deep inspi-
ration breath hold have now been widely introduced into clinic.
Although there is no long-term data to confirm its benefit in term
of major cardiac event reduction, long-term experience shows that
the mean heart’s dose is reduced by 40% (40).
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It must be noted that although the finding of a better cardiac
shielding using APBI is clearly appealing for a cancer population
with excellent survival rates, the long-term outcomes of APBI
remains unknown. If the early outcomes from large trials and
multiple cohort studies appear promising (12, 13, 42, 43), a large
population-based study shows contrariwise a marginal increased
rate of mastectomy likely linked to local recurrence (44). It is even-
tually difficult to evaluate the final impact on the overall survival
when balancing those opposite effects.
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